中药联合化疗改善广泛期小细胞肺癌肿瘤生存的多中心随机单盲安慰剂对照试验方案
研究旨在评估中药联合化疗作为一线治疗能否改善ES-SCLC患者的长期生存,为中药辅助化疗提供高级别证据。
要点
- 中药联合化疗对比化疗 alone 能否改善 ES-SCLC 患者 OS 尚缺乏高级别证据。
- 主要终点为OS,次要终点包括PFS、ORR、生活质量和肿瘤标志物。
核心结论
- 该研究方案旨在确定中药颗粒剂联合化疗能否改善广泛期小细胞肺癌患者的总生存期。
研究设计与样本
- 受试者随机接受4-6个周期(每周期21天)化疗联合中药颗粒剂或安慰剂。
关键数值与推荐
- 主要结局指标为总生存期(OS)。
- 次要结局指标包括无进展生存期(PFS)、客观缓解率(ORR)、生活质量(QoL)和肿瘤标志物。
- 治疗期间每周期结束时进行访视,随访期间每3个月访视一次,直至患者死亡或研究完成。
临床怎么用
- 该试验结果将为中药颗粒剂联合化疗用于ES-SCLC一线治疗提供高级别证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extensive-stage small-cell lung cancer (ES-SCLC) is characterized by extensive metastases, aggressive progression, and poor prognosis. Chemotherapy is applied as a preferred first-line regimen for ES-SCLC, but inadequate for improving its overall survival. Traditional Chinese medicine (TCM) is widely used in the clinical practice of ES-SCLC for its synergy with chemotherapy. However, there is still no substantial evidence to prove that TCM can effectively improve the long-term efficacy of ES-SCLC patients. The study intends to determine whether the TCM with chemotherapy can improve the overall survival (OS) in treating with ES-SCLC when compared with chemotherapy alone. METHOD/DESIGN: A multicenter, randomized, single-blind, placebo-controlled clinical trial will be conducted to determine whether the TCM granules combined with chemotherapy can improve the OS of ES-SCLC. Two hundred seventy participants will randomly receive 4-6 cycles (21 days per cycle) of chemotherapy plus TCM granules or placebo. The primary outcome measure is OS. The secondary outcome measures includes progression-free survival (PFS), objective response rate (ORR), quality of life (QoL), and tumor markers. Visits will be performed at the end of each cycle during the treatment period and then every 3 months in the follow-up period until the patients' death or study completion. DISCUSSION: The study's result will provide a high-level evidence for TCM granules using with chemotherapy on the first-line treatment of ES-SCLC. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900022991 . Registered on 6 May 2019 (prospective registration).
引用
- Chen Y, Yu M, Liu Z, et al. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial. Trials. 2021. PMID: 34238342. doi:10.1186/s13063-021-05407-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。